DK2001456T3 - Anvendelse af kappa-opiodreceptorantagonistholde sammensætninger til behandling af dissociative forstyrrelser - Google Patents

Anvendelse af kappa-opiodreceptorantagonistholde sammensætninger til behandling af dissociative forstyrrelser

Info

Publication number
DK2001456T3
DK2001456T3 DK07727719.2T DK07727719T DK2001456T3 DK 2001456 T3 DK2001456 T3 DK 2001456T3 DK 07727719 T DK07727719 T DK 07727719T DK 2001456 T3 DK2001456 T3 DK 2001456T3
Authority
DK
Denmark
Prior art keywords
treatment
opioid receptor
receptor antagonist
kappa opioid
containing compositions
Prior art date
Application number
DK07727719.2T
Other languages
English (en)
Inventor
Lars-Holger Dr Hermann
Original Assignee
Emodys Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE102006015733A external-priority patent/DE102006015733A1/de
Priority claimed from DE102006016991A external-priority patent/DE102006016991A1/de
Application filed by Emodys Gmbh filed Critical Emodys Gmbh
Application granted granted Critical
Publication of DK2001456T3 publication Critical patent/DK2001456T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
DK07727719.2T 2006-04-04 2007-04-03 Anvendelse af kappa-opiodreceptorantagonistholde sammensætninger til behandling af dissociative forstyrrelser DK2001456T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102006015733A DE102006015733A1 (de) 2006-04-04 2006-04-04 Verwendung von Buprenorphin und Buprenorphin-Derivaten zur Herstellung eines Medikaments zur Behandlung von emotional instabiler Persönlichkeitsstörung, Alkoholabhängigkeit und/oder multipler Substanzabhängigkeit
DE102006016991A DE102006016991A1 (de) 2006-04-11 2006-04-11 Verwendung von kappa-Opioidrezeptor-Antagonisten zur Behandlung von dissoziativen Störungen
PCT/EP2007/053248 WO2007115975A2 (de) 2006-04-04 2007-04-03 Verwendung von zusammensetzungen enthaltend kappa-opioidrezeptor-antagonisten zur behandlung von dissoziativen störungen

Publications (1)

Publication Number Publication Date
DK2001456T3 true DK2001456T3 (da) 2010-04-12

Family

ID=38110094

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07727719.2T DK2001456T3 (da) 2006-04-04 2007-04-03 Anvendelse af kappa-opiodreceptorantagonistholde sammensætninger til behandling af dissociative forstyrrelser

Country Status (17)

Country Link
US (1) US8063059B2 (da)
EP (1) EP2001456B1 (da)
JP (1) JP5128578B2 (da)
AT (1) ATE450256T1 (da)
AU (1) AU2007236003B2 (da)
CA (1) CA2646899C (da)
CY (1) CY1109862T1 (da)
DE (1) DE502007002185D1 (da)
DK (1) DK2001456T3 (da)
EA (1) EA014820B1 (da)
ES (1) ES2337622T3 (da)
HR (1) HRP20100113T1 (da)
PL (1) PL2001456T3 (da)
PT (1) PT2001456E (da)
RS (1) RS51211B (da)
SI (1) SI2001456T1 (da)
WO (1) WO2007115975A2 (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA017484B1 (ru) 2008-01-22 2012-12-28 Эли Лилли Энд Компани Селективный антагонист опиоидных рецепторов каппа
EP3082816B1 (en) 2013-12-20 2019-03-20 Indivior UK Limited Intranasal naloxone compositions and methods of making and using same
MX368870B (es) * 2013-12-20 2019-10-21 H Lundbeck As Uso de un antagonista de receptores de opioides con actividad kappa y vortioxetina para el tratamiento de trastorno depresivo con características melancólicas.
HUE036084T2 (hu) 2014-04-28 2018-06-28 Orphomed Inc Buprenorfin dimer és alkalmazása gasztrointesztinális rendellenességek kezelésénél
US10316021B2 (en) 2016-11-28 2019-06-11 Pfizer Inc. Heteroarylphenoxy benzamide kappa opioid ligands
US12161622B2 (en) 2021-05-04 2024-12-10 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
WO2023170550A1 (en) 2022-03-07 2023-09-14 Janssen Pharmaceuticals, Inc. Polymorph forms of aticaprant for use in treating major depressive disorder
TW202400135A (zh) 2022-03-07 2024-01-01 美商健生醫藥公司 包含阿替卡普蘭之組成物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5028612A (en) 1990-03-22 1991-07-02 Hillel Glover Method for treating emotional numbness
US5780479A (en) * 1997-04-04 1998-07-14 Regents Of The University Of Minnesota Use of opioid antagonists to treat impulse-control disorders
AU2981099A (en) * 1998-03-09 1999-09-27 Trustees Of Tufts College Treatment of compulsive behaviours in man and animals
AU2001275959A1 (en) * 2000-08-15 2002-02-25 Cpd Llc Method of treating the syndrome of type 2 diabetes in humans
US20020045572A1 (en) 2000-08-15 2002-04-18 Cpd, Llc Method of treating the syndrome of type 2 diabetes in humans
US6528518B2 (en) 2000-12-21 2003-03-04 The Mclean Hospital Corporation Treatment of depression with kappa receptor antagonists
US7666876B2 (en) 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
AU2004227833B2 (en) * 2003-04-04 2009-10-01 Merck & Co., Inc. Di-aryl substituted triazole modulators of metabotropic glutamate receptor-5
BRPI0508254A (pt) 2004-03-02 2007-07-24 Pharmacia Corp métodos e composições para o tratamento ou prevenção de distúrbios psiquiátricos com inibidores de cox-2 sozinhos e em combinação com agentes antidepressivos
US7423144B2 (en) * 2004-05-26 2008-09-09 Inotek Pharmaceuticals Corporation Purine Derivatives as adenosine A1 receptor agonists and methods of use thereof
DE602004017514D1 (de) 2004-06-02 2008-12-11 Galephar M F Stabile orale pharmazeutische zusammensetzungen von buprenorphin und salz davon

Also Published As

Publication number Publication date
JP5128578B2 (ja) 2013-01-23
JP2009532434A (ja) 2009-09-10
HRP20100113T1 (hr) 2010-04-30
RS51211B (sr) 2010-12-31
EP2001456A2 (de) 2008-12-17
EA014820B1 (ru) 2011-02-28
AU2007236003B2 (en) 2012-10-18
CA2646899A1 (en) 2007-10-18
AU2007236003A1 (en) 2007-10-18
CY1109862T1 (el) 2014-09-10
CA2646899C (en) 2014-05-06
US8063059B2 (en) 2011-11-22
DE502007002185D1 (de) 2010-01-14
PT2001456E (pt) 2010-03-03
ES2337622T3 (es) 2010-04-27
SI2001456T1 (sl) 2010-04-30
ATE450256T1 (de) 2009-12-15
WO2007115975A3 (de) 2008-02-14
WO2007115975A2 (de) 2007-10-18
EP2001456B1 (de) 2009-12-02
PL2001456T3 (pl) 2010-05-31
EA200802104A1 (ru) 2009-04-28
US20090181999A1 (en) 2009-07-16

Similar Documents

Publication Publication Date Title
CR10379A (es) Composiones farmaceuticas de antagonistas del anticuerpo anti-cd40.
ATE469895T1 (de) Cgrp-rezeptorantagonisten
CY1110882T1 (el) Ανταγωνιστες υποδοχεων ορεξινης υποκατεστημενης διαζεπανης
EP2049110A4 (en) BRAZED DIAZEPANOREXINE RECEPTOR ANTAGONISTS
DE602007012072D1 (de) Orantagonisten
EP2170064A4 (en) 6,5-pyrrolopiperidine tachykinin receptor antagonists
IL208895A0 (en) Nmda receptor antagonists for the treatment of neuropsychiatric disorders
EP2150115A4 (en) CYCLOPROPYLPYRROLIDINOREXIN Receptor Antagonists
DK2152690T3 (da) Pyridylpiperidinorexin-receptorantagonister
PT2570128T (pt) Antagonistas do receptor muscarínico de acetilcolina
BRPI0717937A2 (pt) Compostos de pirazona como antagonistas do receptor mineralocorticóide
DK1729753T3 (da) Anvendelse af en NMDA-receptor-antagonist til behandling af tinnitus induceret ved kokleær excitotoksicitet
ATE509928T1 (de) 8-azabicycloä3.2.1üoktan-verbindungen als mu- opioid-rezeptorantagonisten
EP2350304A4 (en) ANTAGONISTS OF THE GREAT-SIMILAR RECEPTOR 3
EP1765805A4 (en) CGRP RECEPTOR ANTAGONISTS
CY2014030I1 (el) Θεραπευτικες συνθεσεις που περιλαμβανουν ingenol-3-angelate
SI2001456T1 (sl) Uporaba zmesi, ki vsebuje antagonist na opioidnem kapa receptorju za zdravljenje disocialnih bolezni
SG163564A1 (en) Kinin antagonists for treating bladder dysfunction
ATE382034T1 (de) Hydroisoindolin-tachykininrezeptorantagonisten
CL2007002611A1 (es) Compuestos derivados de eter diarilico, antagonistas de los receptores opioides mu, kappa y delta; composicion farmaceutica; y uso para el tratamiento de la obesidad.
DK1973886T3 (da) Prokineticin-1-receptor-antagonister
EP2075252A4 (en) NK1 Receptor Antagonists COMPOSITION
LT3456340T (lt) Glp-1 receptoriaus antagonistas, skirtas įgimto hiperinsulinizmo gydymui
DK2091938T3 (da) Piperidinylaminopyridaziner og anvendelse deraf som hurtigt opløsende antagonister af dopamin-2-receptorer
EP2257534A4 (en) 3-aminoalkyl-1,4-diazepan-2-one melanocortin-5 receptor antagonists